Bosulif: protein kinase inhibitor for chronic myeloid leukaemia

Bosulif (bosutinib) is indicated in chronic, accelerated or blast phase Philadelphia chromosome positive chronic myeloid leukaemia (CML) previously treated with one or more tyrosine kinase inhibitors and where imatinib, nilotinib and dasatinib are not appropriate.

Bosulif (bosutinib) is licensed for chronic myeloid leukaemia (blood cells from bone marrow in a case of CML, pictured) | SCIENCE PHOTO LIBRARY
Bosulif (bosutinib) is licensed for chronic myeloid leukaemia (blood cells from bone marrow in a case of CML, pictured) | SCIENCE PHOTO LIBRARY

PHARMACOLOGY

Bosutinib is a protein kinase inhibitor which inhibits the abnormal Bcr-Abl kinase that promotes CML.1

CLINICAL STUDIES

Bosutinib was evaluated in a phase I/II open-label study involving 570 patients with chronic, accelerated or blast phase, imatinib-resistant or imatinib-intolerant CML that had been previously treated with at least one tyrosine kinase inhibitor.1

Marketing approval was granted primarily on the basis of findings in 52 patients deemed as having an unmet medical need because other tyrosine kinase inhibitors were not appropriate due to resistance or the risk of adverse effects. Of these, 36 had chronic phase CML and 16 had either accelerated or blast phase CML.1

In patients with chronic phase CML treated previously with imatinib only, 59% (95% CI 52.9-65.0) achieved a major cytogenetic response (MCyR) at week 24 (primary efficacy endpoint). This compared with 40.9% (95% CI 31.6-50.7) of those treated previously with imatinib and dasatinib or nilotinib.1

In patients with accelerated or blast phase CML treated previously with at least imatinib, the proportions achieving MCyR at week 24 were 34.8% (95% CI 23.7-47.2) and 29.6% (95% CI 18.0-43.6), respectively.1

The most commonly reported adverse effects were GI upset, thrombocytopenia, rash, anaemia, pyrexia and raised serum ALT. 1

Bosulif has been given conditional marketing approval pending further evidence of clinical benefit and safety.

References:

  1. Bosulif Summary of Product Characteristics, March 2013

View Bosulif drug record

Further information: Pfizer

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.